½ÃÀ庸°í¼­
»óǰÄÚµå
1720882

¼¼°èÀÇ ÇÏÁöºÒ¾È ÁõÈıº ½ÃÀå º¸°í¼­(2025³â)

Restless Leg Syndrome Global Market Report 2025

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: The Business Research Company | ÆäÀÌÁö Á¤º¸: ¿µ¹® 175 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

ÇÏÁöºÒ¾È ÁõÈıº ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ ±Þ¼ºÀåÀÌ Àü¸ÁµÉ ¿¹Á¤ÀÔ´Ï´Ù. ÀÇ·á ÅõÀÚ Áõ°¡, ÀÎ½Ä ¹× ±³À° Ä·ÆäÀÎ, Á¶±â Áø´Ü Áõ°¡, Á¤ºÎ ÀÚ±Ý Áõ°¡, ÀÓ»ó½ÃÇè Âü¿© Áõ°¡ µîÀÇ ¿äÀο¡ ±âÀÎÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¹Ãø ±â°£ÀÇ ÁÖ¿ä µ¿Çâ¿¡´Â AI¸¦ Ȱ¿ëÇÑ ¸ÂÃãÇü Ä¡·á °èȹ, Â÷¼¼´ë ½Å°æ ÀÚ±Ø ÀåÄ¡, Áø´ÜÀ» À§ÇÑ µö·¯´× ¾Ë°í¸®Áò, ³úÆÄ º¯Á¶ ±â¼ú, ´Ù¸®ÀÇ ¿òÁ÷ÀÓÀ» º¸Á¶Çϵµ·Ï ¼³°èµÈ ¿þ¾î·¯ºí ¿Ü°ñ°Ý µîÀÌ ÀÖ½À´Ï´Ù.

ö °áÇÌÁõÀÇ À¯º´·ü Áõ°¡´Â ÇÏÁöºÒ¾È ÁõÈıº(RLS) ½ÃÀåÀÇ È®´ë¸¦ ÃËÁøÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. öºÐ °áÇÌÀº ½Åü°¡ ÃæºÐÇÑ Ã¶ºÐÀÌ ºÎÁ·ÇÏ¿© ÃæºÐÇÑ °Ç°­ÇÑ ÀûÇ÷±¸¸¦ »ý¼ºÇÏÁö ¸øÇÏ´Â »óÅ·Î, ÇÇ·Î, ¼è¾à, â¹éÇÑ ÇÇºÎ¿Í °°Àº Áõ»óÀ» À¯¹ßÇÕ´Ï´Ù. öºÐ °áÇÌÁõ Áõ°¡´Â ºÒÃæºÐÇÑ ½Ä»ç ¼·Ãë, ÃâÇ÷, Èí¼ö Àå¾Ö, ÀӽŠÁß ¹× ¼ºÀå±âÀÇ Ã¶ ¼ö¿ä Áõ°¡ µîÀÇ ¿äÀο¡ ÀÇÇÑ °ÍÀÔ´Ï´Ù. ½ÄǰÀÇ Á¶Á¤ÀÌ Æ÷ÇÔµÇ¾î ºÒÄèÇÑ Ãæµ¿°ú °¨°¢À» ¿ÏÈ­ÇÒ»Ó¸¸ ¾Æ´Ï¶ó ö ÀúÀå·®ÀÇ º¸Ãæ, ÀûÇ÷±¸ »ý»êÀÇ °³¼±, ÀûÀýÇÑ ½Å°æ ±â´ÉÀÇ È¸º¹¿¡ ÀÇÇØ ±Ùº»ÀûÀΠö °áÇÌÁõ¿¡ ´ëóÇÕ´Ï´Ù. 2025³â 1¿ù NHS À×±Û·£µå´Â 2023-24³â ö °áÇÌÀ¸·Î ÀÎÇÑ ÀÔ¿ø ȯÀÚ ¼ö°¡ 19¸¸ 1,927¸íÀ¸·Î Àü³âµµ¿¡¼­ 11% Áõ°¡Çß´Ù°í º¸°íÇßÀ¸¸ç, ±× °á°ú ö °áÇÌÁõÀÇ À¯º´·ü »ó½ÂÀÌ RLS ½ÃÀå ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

RLS ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº Áõ»ó °ü¸®¿Í ȯÀÚ °á°ú¸¦ °³¼±ÇÏ´Â Çõ½ÅÀûÀÎ ºñħ½ÀÀû Ä¡·á¹ýÀÇ °³¹ß¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. ÀÚ±Ø, ±¤¼±Ä¡·á, ¿ÜºÎ±â±â µîÀÇ Ã·´Ü±â¼ú¿¡ ÀÇÇØ ¿ÏÈ­¸¦ °¡Á®¿É´Ï´Ù. Á÷¼º ¿îµ¿ Ȱ¼ºÈ­(TOMAC) ½Ã½ºÅÛÀÇ FDA µ¥³ëº¸ ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù. ÀÌ ÀåÄ¡´Â ½ÅüÀÇ ¾çÂÊ¿¡ ÀÖ´Â ºñ°ñ ½Å°æÀ» Àü±âÀûÀ¸·Î Ȱ¼ºÈ­½ÃÄÑ °­Á÷Çϰí Áö¼ÓÀûÀÎ ±ÙÀ°ÀÇ È°¼ºÈ­¸¦ °¡Á®¿À°í, ¼ö¸é°ú ¾ç¸³Çϸ鼭 RLS Áõ»óÀÇ ¾ïÁ¦¸¦ º¸Á¶ÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - °Å½Ã°æÁ¦ ½Ã³ª¸®¿À ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ½ÅÇü Äڷγª ¹ÙÀÌ·¯½º °¨¿°ÀÇ ¿µÇâ°ú ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

  • ¼¼°èÀÇ ÇÏÁöºÒ¾È ÁõÈıº PESTEL ºÐ¼®(Á¤Ä¡, »çȸ, ±â¼ú, ȯ°æ, ¹ýÀû ¿äÀÎ, ÃËÁø¿äÀΰú ¾ïÁ¦¿äÀÎ)
  • ÃÖÁ¾ ÀÌ¿ë »ê¾÷ÀÇ ºÐ¼®
  • ¼¼°èÀÇ ÇÏÁöºÒ¾È ÁõÈıº ½ÃÀå : ¼ºÀå·ü ºÐ¼®
  • ¼¼°èÀÇ ÇÏÁöºÒ¾È ÁõÈıº ½ÃÀå ½ÇÀû : ±Ô¸ð¿Í ¼ºÀå, 2019-2024
  • ¼¼°èÀÇ ÇÏÁöºÒ¾È ÁõÈıº ½ÃÀå ¿¹Ãø : ±Ô¸ð¿Í ¼ºÀå, 2024-2029, 2034F
  • ¼¼°èÀÇ ÇÏÁöºÒ¾È ÁõÈıº Àüü ½ÃÀå ±Ô¸ð(TAM)

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

  • ¼¼°èÀÇ ÇÏÁöºÒ¾È ÁõÈıº ½ÃÀå : À¯Çüº°, ºÐ¼®°ú ¿¹Ãø, 2019-2024, 2024-2029F, 2034F
  • ¿ø¹ß¼º ÇÏÁöºÒ¾È ÁõÈıº
  • 2Â÷¼º ÇÏÁöºÒ¾È ÁõÈıº
  • ¼¼°èÀÇ ÇÏÁöºÒ¾È ÁõÈıº ½ÃÀå : Ä¡·áÀ¯Çüº°, ºÐ¼®°ú ¿¹Ãø, 2019-2024, 2024-2029F, 2034F
  • ÀǾàǰ ¹× ÀÇ·á±â±â
  • ¼ö¼ú
  • ¼¼°èÀÇ ÇÏÁöºÒ¾È ÁõÈıº ½ÃÀå : Åõ¿© °æ·Îº°, ºÐ¼®°ú ¿¹Ãø, 2019-2024, 2024-2029F, 2034F
  • ¿À¶ö
  • ÁÖ»çÁ¦
  • ¼¼°èÀÇ ÇÏÁöºÒ¾È ÁõÈıº ½ÃÀå : À¯Åë ä³Îº°, ºÐ¼®°ú ¿¹Ãø, 2019-2024, 2024-2029F, 2034F
  • º´¿ø ¾à±¹
  • ¼Ò¸Å ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹
  • ¼¼°èÀÇ ÇÏÁöºÒ¾È ÁõÈıº ½ÃÀå : ¿ëµµº°, ºÐ¼®°ú ¿¹Ãø, 2019-2024, 2024-2029F, 2034F
  • ½Å°æÇÐÀû Ä¡·á
  • ¼ö¸éÀå¾Ö
  • ¿îµ¿Àå¾Ö
  • Áõ»ó °ü¸®
  • ¼¼°èÀÇ ÇÏÁöºÒ¾È ÁõÈıº ½ÃÀå : ¿ø¹ß¼º ÇÏÁöºÒ¾È ÁõÈıºÀÇ À¯Çüº° ¼¼ºÐÈ­, ºÐ¼®°ú ¿¹Ãø, 2019-2024, 2024-2029F, 2034F
  • Ư¹ß¼º ÇÏÁöºÒ¾È ÁõÈıº
  • À¯Àü¼º ÇÏÁöºÒ¾È ÁõÈıº
  • 2014-2029F
  • ö °áÇ̼º ÇÏÁöºÒ¾È ÁõÈıº
  • ¸¸¼º ½ÅÀ庴 °ü·Ã ÇÏÁöºÒ¾È ÁõÈıº
  • Àӽаü·Ã ÇÏÁöºÒ¾È ÁõÈıº
  • ¾àÁ¦ À¯¹ß¼º ÇÏÁöºÒ¾È ÁõÈıº

Á¦7Àå Áö¿ªº°, ±¹°¡º° ºÐ¼®

  • ¼¼°èÀÇ ÇÏÁöºÒ¾È ÁõÈıº ½ÃÀå : Áö¿ªº°, ºÐ¼®°ú ¿¹Ãø, 2019-2024, 2024-2029F, 2034F
  • ¼¼°èÀÇ ÇÏÁöºÒ¾È ÁõÈıº ½ÃÀå : ±¹°¡º°, ºÐ¼®°ú ¿¹Ãø, 2019-2024, 2024-2029F, 2034F

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • ÇÏÁöºÒ¾È ÁõÈıº ½ÃÀå : °æÀï ±¸µµ
  • ÇÏÁöºÒ¾È ÁõÈıº ½ÃÀå : ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
    • Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Novartis International AG Overview, Products and Services, Strategy and Financial Analysis
    • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

  • Teva Pharmaceutical Industries Ltd.
  • Boehringer Ingelheim International GmbH
  • Baxter International Inc.
  • Astellas Pharma Inc.
  • UCB SA
  • Kyowa Kirin Co Ltd.
  • Amneal Pharmaceuticals Inc.
  • Lupin Pharmaceuticals Inc.
  • Alembic Pharmaceuticals Limited
  • Mundipharma International Limited
  • Azurity Pharmaceuticals LLC
  • Otsuka Pharmaceutical Co Ltd.
  • Horizon Therapeutics plc
  • Mylan NV
  • Apollo Pharmacy Limited

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

  • ÇÏÁöºÒ¾È ÁõÈıº ½ÃÀå(2029³â) : »õ·Î¿î ±âȸ¸¦ Á¦°øÇÏ´Â ±¹°¡
  • ÇÏÁöºÒ¾È ÁõÈıº ½ÃÀå(2029³â) : »õ·Î¿î ±âȸ¸¦ Á¦°øÇÏ´Â ºÎ¹®
  • ÇÏÁöºÒ¾È ÁõÈıº ½ÃÀå(2029³â) : ¼ºÀå Àü·«
    • ½ÃÀå µ¿Çâ¿¡ ±âÃÊÇÑ Àü·«
    • °æÀï Àü·«

Á¦36Àå ºÎ·Ï

SHW 25.05.19

Restless Leg Syndrome (RLS) is a neurological disorder defined by an overwhelming urge to move the legs, often caused by uncomfortable sensations. Treatment options include lifestyle modifications, iron supplements, medications that influence dopamine levels, and methods to enhance sleep hygiene.

The primary types of restless leg syndrome are primary restless leg syndrome and secondary restless leg syndrome. Primary restless leg syndrome occurs when the symptoms of restless legs appear without any underlying medical condition. Treatments for these conditions include medicines, devices, and, in some cases, surgery. These treatments are available through different routes of administration, such as oral and injectable forms. They are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and are used in a range of applications such as neurological care, sleep disorder management, movement disorders, and symptom control.

The restless leg syndrome market research report is one of a series of new reports from The Business Research Company that provide restless leg syndrome market statistics, including restless leg syndrome industry global market size, regional shares, competitors with a restless leg syndrome market share, detailed restless leg syndrome market segments, market trends and opportunities, and any further data you may need to thrive in the restless leg syndrome industry. This restless leg syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The restless leg syndrome market size has grown rapidly in recent years. It will grow from $1.91 billion in 2024 to $2.17 billion in 2025 at a compound annual growth rate (CAGR) of 13.8%. The growth during the historic period can be attributed to factors such as rising alcohol consumption, expanded health insurance coverage, greater availability of over-the-counter medications, increased public health initiatives, and a rise in mental health concerns.

The restless leg syndrome market size is expected to see rapid growth in the next few years. It will grow to $3.59 billion in 2029 at a compound annual growth rate (CAGR) of 13.4%. The growth during the forecast period can be attributed to factors such as increased healthcare investment, awareness and education campaigns, a rise in early diagnoses, higher government funding, and greater participation in clinical trials. Key trends in the forecast period include AI-powered personalized treatment plans, next-generation neurostimulation devices, deep learning algorithms for diagnosis, brainwave modulation technology, and wearable exoskeletons designed to assist with leg movements.

The growing prevalence of iron deficiency is expected to drive the expansion of the restless leg syndrome (RLS) market. Iron deficiency is a condition in which the body lacks sufficient iron to produce enough healthy red blood cells, leading to symptoms such as fatigue, weakness, and pale skin. The rise in iron deficiency cases is attributed to factors such as poor dietary intake, blood loss, malabsorption disorders, and increased iron demands during pregnancy or growth. Treatment for restless leg syndrome often includes iron supplementation or dietary adjustments, which not only help alleviate the discomforting urges and sensations but also address the underlying iron deficiency by replenishing iron stores, improving red blood cell production, and restoring proper neurological function. For example, in January 2025, NHS England reported that in the 2023-24 period, there were 191,927 admissions due to iron deficiency, reflecting an 11% increase from the previous year. As a result, the rising prevalence of iron deficiency is fueling the growth of the RLS market.

Leading companies in the RLS market are focusing on developing innovative, non-invasive therapies to improve symptom management and patient outcomes. Non-invasive therapies are medical treatments that do not require surgery or skin penetration, offering relief through advanced techniques such as electrical stimulation, light therapy, or external devices. For example, in April 2023, Varco Leg Care, an India-based consumer health-technology company, received FDA De Novo approval for its NTX100 Tonic Motor Activation (TOMAC) System. This system is designed to treat moderate to severe RLS symptoms and improve sleep quality in patients who do not respond to medications. The device works by electrically activating the peroneal nerves on both sides of the body to produce tonic, sustained muscle activation, which aids in suppressing RLS symptoms while being compatible with sleep.

In October 2023, Amgen Inc., a US-based biotechnology company, acquired Horizon Therapeutics plc for an undisclosed amount. This acquisition aims to strengthen Amgen's portfolio in rare and inflammatory diseases, drive revenue growth, and develop innovative treatments while improving patient access to medications. Horizon Therapeutics plc, an Ireland-based biotechnology company, is involved in the treatment of restless leg syndrome.

Major players in the restless leg syndrome market are Pfizer Inc., Roche Holding AG, Merck & Co Inc., Novartis International AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Baxter International Inc., Astellas Pharma Inc., UCB S.A., Kyowa Kirin Co Ltd., Amneal Pharmaceuticals Inc., Lupin Pharmaceuticals Inc., Alembic Pharmaceuticals Limited, Mundipharma International Limited, Azurity Pharmaceuticals LLC, Otsuka Pharmaceutical Co Ltd., Horizon Therapeutics plc, Mylan N.V., Apollo Pharmacy Limited.

Europe was the largest region in the restless leg syndrome market in 2024. North-America is expected to be the fastest-growing region in the forecast period. The regions covered in restless leg syndrome report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the restless leg syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The restless leg syndrome market consists of sales of benzodiazepines, sleep aids, transdermal patches, non-pharmacological therapies, and lifestyle management tools. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Restless Leg Syndrome Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on restless leg syndrome market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for restless leg syndrome ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The restless leg syndrome market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Primary Restless Legs Syndrome; Secondary Restless Legs Syndrome
  • 2) By Treatment Type: Medicine And Devices; Surgery
  • 3) By Route Of Administration: Oral; Injectable
  • 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
  • 5) By Application: Neurological Treatment; Sleep Disorders; Movement Disorders; Symptom Management
  • Subsegments:
  • 1) By Primary Restless Legs Syndrome: Idiopathic Restless Legs Syndrome; Hereditary Restless Legs Syndrome
  • 2) By Secondary Restless Legs Syndrome: Iron Deficiency-related Restless Legs Syndrome; Chronic Kidney Disease-related Restless Legs Syndrome; Pregnancy-related Restless Legs Syndrome; Medication-induced Restless Legs Syndrome
  • Companies Mentioned:Pfizer Inc.; Roche Holding AG; Merck & Co Inc.; Novartis International AG; GlaxoSmithKline plc
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Restless Leg Syndrome Market Characteristics

3. Restless Leg Syndrome Market Trends And Strategies

4. Restless Leg Syndrome Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Restless Leg Syndrome Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Restless Leg Syndrome PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Restless Leg Syndrome Market Growth Rate Analysis
  • 5.4. Global Restless Leg Syndrome Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Restless Leg Syndrome Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Restless Leg Syndrome Total Addressable Market (TAM)

6. Restless Leg Syndrome Market Segmentation

  • 6.1. Global Restless Leg Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Primary Restless Legs Syndrome
  • Secondary Restless Legs Syndrome
  • 6.2. Global Restless Leg Syndrome Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Medicine And Devices
  • Surgery
  • 6.3. Global Restless Leg Syndrome Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oral
  • Injectable
  • 6.4. Global Restless Leg Syndrome Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • 6.5. Global Restless Leg Syndrome Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Neurological Treatment
  • Sleep Disorders
  • Movement Disorders
  • Symptom Management
  • 6.6. Global Restless Leg Syndrome Market, Sub-Segmentation Of Primary Restless Legs Syndrome, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Idiopathic Restless Legs Syndrome
  • Hereditary Restless Legs Syndrome
  • 6.7. Global Restless Leg Syndrome Market, Sub-Segmentation Of Secondary Restless Legs Syndrome, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Iron Deficiency-related Restless Legs Syndrome
  • Chronic Kidney Disease-related Restless Legs Syndrome
  • Pregnancy-related Restless Legs Syndrome
  • Medication-induced Restless Legs Syndrome

7. Restless Leg Syndrome Market Regional And Country Analysis

  • 7.1. Global Restless Leg Syndrome Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Restless Leg Syndrome Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Restless Leg Syndrome Market

  • 8.1. Asia-Pacific Restless Leg Syndrome Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Restless Leg Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Restless Leg Syndrome Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Restless Leg Syndrome Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Restless Leg Syndrome Market

  • 9.1. China Restless Leg Syndrome Market Overview
  • 9.2. China Restless Leg Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Restless Leg Syndrome Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Restless Leg Syndrome Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Restless Leg Syndrome Market

  • 10.1. India Restless Leg Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Restless Leg Syndrome Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Restless Leg Syndrome Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Restless Leg Syndrome Market

  • 11.1. Japan Restless Leg Syndrome Market Overview
  • 11.2. Japan Restless Leg Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Restless Leg Syndrome Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Restless Leg Syndrome Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Restless Leg Syndrome Market

  • 12.1. Australia Restless Leg Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Restless Leg Syndrome Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Restless Leg Syndrome Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Restless Leg Syndrome Market

  • 13.1. Indonesia Restless Leg Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Restless Leg Syndrome Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Restless Leg Syndrome Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Restless Leg Syndrome Market

  • 14.1. South Korea Restless Leg Syndrome Market Overview
  • 14.2. South Korea Restless Leg Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Restless Leg Syndrome Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Restless Leg Syndrome Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Restless Leg Syndrome Market

  • 15.1. Western Europe Restless Leg Syndrome Market Overview
  • 15.2. Western Europe Restless Leg Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Restless Leg Syndrome Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Restless Leg Syndrome Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Restless Leg Syndrome Market

  • 16.1. UK Restless Leg Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Restless Leg Syndrome Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Restless Leg Syndrome Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Restless Leg Syndrome Market

  • 17.1. Germany Restless Leg Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Restless Leg Syndrome Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Restless Leg Syndrome Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Restless Leg Syndrome Market

  • 18.1. France Restless Leg Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Restless Leg Syndrome Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Restless Leg Syndrome Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Restless Leg Syndrome Market

  • 19.1. Italy Restless Leg Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Restless Leg Syndrome Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Restless Leg Syndrome Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Restless Leg Syndrome Market

  • 20.1. Spain Restless Leg Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Restless Leg Syndrome Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Restless Leg Syndrome Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Restless Leg Syndrome Market

  • 21.1. Eastern Europe Restless Leg Syndrome Market Overview
  • 21.2. Eastern Europe Restless Leg Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Restless Leg Syndrome Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Restless Leg Syndrome Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Restless Leg Syndrome Market

  • 22.1. Russia Restless Leg Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Restless Leg Syndrome Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Restless Leg Syndrome Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Restless Leg Syndrome Market

  • 23.1. North America Restless Leg Syndrome Market Overview
  • 23.2. North America Restless Leg Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Restless Leg Syndrome Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Restless Leg Syndrome Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Restless Leg Syndrome Market

  • 24.1. USA Restless Leg Syndrome Market Overview
  • 24.2. USA Restless Leg Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Restless Leg Syndrome Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Restless Leg Syndrome Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Restless Leg Syndrome Market

  • 25.1. Canada Restless Leg Syndrome Market Overview
  • 25.2. Canada Restless Leg Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Restless Leg Syndrome Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Restless Leg Syndrome Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Restless Leg Syndrome Market

  • 26.1. South America Restless Leg Syndrome Market Overview
  • 26.2. South America Restless Leg Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Restless Leg Syndrome Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Restless Leg Syndrome Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Restless Leg Syndrome Market

  • 27.1. Brazil Restless Leg Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Restless Leg Syndrome Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Restless Leg Syndrome Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Restless Leg Syndrome Market

  • 28.1. Middle East Restless Leg Syndrome Market Overview
  • 28.2. Middle East Restless Leg Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Restless Leg Syndrome Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Restless Leg Syndrome Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Restless Leg Syndrome Market

  • 29.1. Africa Restless Leg Syndrome Market Overview
  • 29.2. Africa Restless Leg Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Restless Leg Syndrome Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Restless Leg Syndrome Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Restless Leg Syndrome Market Competitive Landscape And Company Profiles

  • 30.1. Restless Leg Syndrome Market Competitive Landscape
  • 30.2. Restless Leg Syndrome Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

31. Restless Leg Syndrome Market Other Major And Innovative Companies

  • 31.1. Teva Pharmaceutical Industries Ltd.
  • 31.2. Boehringer Ingelheim International GmbH
  • 31.3. Baxter International Inc.
  • 31.4. Astellas Pharma Inc.
  • 31.5. UCB S.A.
  • 31.6. Kyowa Kirin Co Ltd.
  • 31.7. Amneal Pharmaceuticals Inc.
  • 31.8. Lupin Pharmaceuticals Inc.
  • 31.9. Alembic Pharmaceuticals Limited
  • 31.10. Mundipharma International Limited
  • 31.11. Azurity Pharmaceuticals LLC
  • 31.12. Otsuka Pharmaceutical Co Ltd.
  • 31.13. Horizon Therapeutics plc
  • 31.14. Mylan N.V.
  • 31.15. Apollo Pharmacy Limited

32. Global Restless Leg Syndrome Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Restless Leg Syndrome Market

34. Recent Developments In The Restless Leg Syndrome Market

35. Restless Leg Syndrome Market High Potential Countries, Segments and Strategies

  • 35.1 Restless Leg Syndrome Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Restless Leg Syndrome Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Restless Leg Syndrome Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦